Roche Holding AG  

(Public, ETR:RHO5)   Watch this stock  
Find more results for JOHN DOES, 1-3
106.90
-0.45 (-0.42%)
Oct 19 - Close
ETR data delayed by 15 mins - Disclaimer
Currency in EUR
Range 106.00 - 107.50
52 week 97.67 - 127.75
Open 107.25
Vol. 7,505.00
Mkt cap 0.00
P/E     -
Div/yield     -
EPS     -
Shares     -
Beta     -
Inst. own     -
Sep 29, 2015
Roche Holding AG at Sanford C Bernstein European Strategic Decisions Conference Add to calendar
Sep 17, 2015
Roche Holding AG at Morgan Stanley Healthcare Conference Add to calendar
Sep 16, 2015
Roche Holding AG at Bank of America Merrill Lynch Global Healthcare Conference Add to calendar
Sep 9, 2015
Roche Holding AG at Goldman Sachs European Medtech and Healthcare Services Conference Add to calendar
Aug 13, 2015
Roche Holding AG at UBS Genomics 2.0 Summit Add to calendar
Jul 29, 2015
Roche Holding AG Analyst Event on Diagnostics Division at AACC 2015 - 12:00AM GMT+2 - Add to calendar
Jul 23, 2015
Half Year 2015 Roche Holding AG Earnings Call - 1:00PM GMT+2 - Add to calendar
Jul 23, 2015
Half Year 2015 Roche Holding AG Earnings Release - 7:00AM GMT+2 - Add to calendar
Jun 25, 2015
Roche Holding AG at JPMorgan European Healthcare Conference
Jun 17, 2015
Roche Holding AG at Deutsche Bank dbAcces German, Swiss & Austrian Conference
  

Address

Grenzacherstr. 124
BASEL, 4070
Switzerland
+41-9-732354295 (Phone)

Website links

External links

Description

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. It operates worldwide containing the United States, Western Europe, Japan and Asia-Pacific, among others. Diagnostics include five areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan. In September 2014, it accepted for payment of all shares of InterMune Inc. through its wholly owned subsidiary Klee Acquisition Corporation. Additionally, it offers hardware and software solutions for genomic analysis.

Officers and directors

Severin Schwan Chairman of the Corporate Executive Committee, Chief Executive Officer, Director
Age: 47
Alan Hippe Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Age: 47
Stephan Feldhaus Member of the Enlarged Corporate Executive Committee, Head Group Communications
Age: 52
Sophie Kornowski-Bonnet Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Age: 50
Osamu Nagayama Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
Age: 67
John C. Reed M.D., Ph.D. Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Age: 56
Richard H. Scheller Ph.D. Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Age: 61
Urs Jaisli Chief Compliance Officer
Age: 58
Gottlieb A. Keller Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Age: 60
Silvia Ayyoubi Member of the Corporate Executive Committee, Head of Group Human Resources
Age: 61